Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials

Zura Bio Ltd

2026-Q1 EPS reported -$0.22

Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.
R&D expenses $14.7M, up from $10.5M, driven by tibulizumab Phase 2 programs.
Cash $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028.
Phase 2 TibuSHIELD (HS) on track for topline data Q4 2026; TibuSURE (SSc) data expected H1 2027.
Completed $144M public offering in February 2026; appointed new CEO and two board members.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-26-031701
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2026-05-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.153020+00:00
generated_at: 2026-05-14T22:04:34.233228+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-26-031701
json_url: https://secwatch.observer/filing/0001628280-26-031701.json
markdown_url: https://secwatch.observer/filing/0001628280-26-031701.md
text_url: https://secwatch.observer/filing/0001628280-26-031701.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/0001628280-26-031701-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001628280-26-031701

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.